Has "levodopa-induced neuropathy" been reported in Parkinson's disease clinical trials?

Movement Disorders

Volumn 26, Issue 10, 2011, Pages 1966-1967

  Teodoro, Tiago ^a   Pires, Daniela ^a   Rosa, Mário M ^a   Coelho, Miguel ^a   Sampaio, Cristina ^a   Ferreira, Joaquim J ^a  

^a Lisbon School of Medicine   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA; PLACEBO;

CASE CONTROL STUDY; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE COURSE; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; LETTER; MONONEUROPATHY; NEUROPATHY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; POPULATION; PRIORITY JOURNAL; SYMPTOM; SYSTEMATIC REVIEW (TOPIC);

ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEVODOPA; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 80052263786     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23760     Document Type: Letter

References (6)

1. Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 2008; 23: 1850-1859.
2. Toth C, Breithaupt K, Suchowersky O, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010; 68: 28-36.
3. Manca D, Cossu G, Murgia D, et al. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. Mov Disord 2009; 24: 2293-2294.
4. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007; 22: 1145-1149.
5. Urban P, Wellach I, Weis J, et al. Subacute axonal neuropathy in Parkinson's Disease with cobalamine and vitamin B6 deficiency under duodopa therapy. Mov Disord 2010; 25: 1748-1752.
6. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.